The underpinning mechanism may be that CD22 and other B cell markers are still expressed on CD19‐negative tumour cells, making the combinational targeting of CD19 and other tumour‐associated antigens a feasible and superior solution compared to single targeting of CD19 in TP53‐disrupted B cell malignancies [1, 42, 46]. Here, CD19 is linked to neoplasm.